CDK4 and neoplasm: Likewise, antagonizing AR function in combination with CDK4/6 inhibition (abemaciclib) suppresses TNBC tumor growth [135], the direct opposite of that observed for luminal disease where AR agonism synergized with CDK4/6 inhibition (palbociclib) to block growth [121].